RO7017773 + itraconazole

RO7017773 + itraconazole is an investigational **combination of two small molecule pharmaceuticals**: RO7017773, a novel agent being studied in neurodevelopmental disorders such as autism spectrum disorder, and itraconazole, a long-approved azole antifungal drug. RO7017773’s precise mechanism of action is not publicly detailed but is under active research as a potential treatment for neurodevelopmental conditions. Itraconazole acts by inhibiting fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase, disrupting ergosterol synthesis critical for fungal cell membrane integrity. Additionally, itraconazole is a **potent inhibitor of CYP3A4, P-glycoprotein, and breast cancer resistance protein (BCRP)**, leading to clinically important drug-drug interactions. No clinical or investigational data were found for formal uses of this exact combination; most information pertains to each agent individually[1][2][3][4][5][6].

Brand names

SporAnox

Other names

itraconazole